Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Ginecol Obstet Mex ; 80(7): 467-72, 2012 Jul.
Artigo em Espanhol | MEDLINE | ID: mdl-22916640

RESUMO

Vasomotor symptoms are one of the main reasons for climateric women to consult a physician. Hormone therapy is the first treatment choice, but it is not indicated to all patients. Veralipride is an option for those who cannot or will not try hormone treatment. The Mexican Association for the Study of Climateric (AMEC) assembled an interdisciplinary group of medical experts so that they revised the medical literature on the subject and reached a consensus on veralipride indication, doses, counterindications and safety. The recommendations of the consensus conference on veralipride are: (1) Physicians must be familiar with its indication, side effects, pharmacokinetics and dosage. (2) Patients must be informed on other therapeutical options. (3) Patients' mental and neurological state must be evaluated, in particular to identify movement disorders, extrapyramidal symptoms (tremor or dystonia), anxiety and depression that can be mistaken for climateric symptoms. (4) Any adverse effect associated with the drug must be reported. (5) A random multicenter trial must be carried out in order to identify the frequency and severity of side effects, and (6) Written information on possible health risks when using the drug must be provided.


Assuntos
Menopausa , Sulpirida/análogos & derivados , Sistema Vasomotor/efeitos dos fármacos , Sistema Vasomotor/fisiopatologia , Feminino , Humanos , Americanos Mexicanos , Seleção de Pacientes , Sulpirida/uso terapêutico
2.
Ginecol Obstet Mex ; 71: 379-86, 2003 Aug.
Artigo em Espanhol | MEDLINE | ID: mdl-14619691

RESUMO

The preeclampsia is the first cause of maternal morbility, with increase in the obstetric complications when it is associated to HELLP syndrome, for the low platelets that even involves to the neonate. This study was carried out in the patients accepted in the intensive Adults Cares Unit in the period of one year, surgical complications and the perinatal results were determined in women with low platelet count for HELLP syndrome in preeclampsia-eclampsia. Three groups were formed according to the platelets account and then were analyzed using chi square to determine association among these groups of patients, as well as mean and standard deviation (M +/- DE) to describe results. Forty patients were studied with low platelets by HELLP syndrome in preeclampsia-eclampsia, where the distribution for the group with platelets < 50,000 were 12 patients (30%), in the group among 51,000-100,000 of 18 cases (45%), and of 101,000-150,000 were of 10 cases (25%). The mean of gestas was of 2.3 +/- 1.2, more frequent delivery was for cesarean section in 39 cases (97.5%) and a single case for vaginal via (2.5%), a maternal death was presented (8.3%). The surgical reintervention was observed with more frequency in the group of < 50,000 platelets, the most frequent cause in these reinterventions was the hipovolemic shock. Also in this group the perinatal mortality was presented in 3 cases (25%) and the asphyxia at the birth with Apgar < 6 was presented in 5 cases (41.7%). A bigger morbility was observed inversely proportional to the account platelets, being the renal failure the cause most frequent of this morbility in the three groups. The low platelets account contribute in a direct way in the obstetric complications, since there are more surgical reinterventions, with bled in the transsurgical and increase in the days of intrahospitalary stay. Also with smaller account platelet, there are bigger prematural index, asphyxia and perinatal mortality in the newborn of mothers with HELLP syndrome.


Assuntos
Cesárea/efeitos adversos , Síndrome HELLP/complicações , Pré-Eclâmpsia/complicações , Resultado da Gravidez , Trombocitopenia/etiologia , Adulto , Parto Obstétrico/efeitos adversos , Eclampsia/sangue , Eclampsia/complicações , Eclampsia/mortalidade , Feminino , Idade Gestacional , Síndrome HELLP/sangue , Síndrome HELLP/mortalidade , Humanos , Mortalidade Infantil , Recém-Nascido , Mortalidade Materna , Contagem de Plaquetas , Pré-Eclâmpsia/sangue , Pré-Eclâmpsia/mortalidade , Gravidez , Complicações na Gravidez , Trombocitopenia/sangue , Trombocitopenia/mortalidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA